

Genetic Diversity Survey

Elizabeth Pennisi, in her News & Comment article about a new National Research Council (NRC) report "Evaluating human genetic diversity" (24 Oct. p. 568), states that the committee (which I chaired) that wrote the report gave "a cautious nod of approval" to a proposed global survey of human genetic diversity. The committee strongly endorses such a survey, provided that it is conducted in a way that protects the individual identities and rights of the participants. However, contrary to what the article says, the committee neither approved nor disapproved of the so-called "consensus document" that has been identified as the Human Genome Diversity Project, although we have taken issue with some of the recommendations in the consensus statement. As stated in the executive summary of our report, after an exhaustive examination, the committee found that this document does not clearly explain the purpose of the project or provide the necessary safeguards for protecting participants. Accordingly, the committee focused its attention on the scientific merits of a global study of human genetic variation and the ethical, legal, and organizational difficulties such a study would have to confront.

William J. Schull
Committee on Human Genome Diversity,
Board on Biology,
Commission on Life Sciences,
National Research Council,
Washington, DC 20418, USA

SIV Vaccine for AIDS


Jon Cohen, in his News article "Weakened SIV [simian immunodeficiency virus] vaccine still kills" (3 Oct., p. 24), cites several researchers' data that a percentage (<5%) of monkeys in different clinical trials have developed immunodeficiency or AIDS, or both, after infection with human immunodeficiency virus (HIV). He also quotes the criticisms of several researchers about the publicity surrounding the International Association of Physicians in AIDS Care (IAPAC) initiative to recruit physician volunteers for a safety trial with live attenuated HIV.


Not quoted are observations from Australia (1) and from Massachusetts (2) of 19 humans who were accidentally infected with HIV deficient only in the *nef* gene 10 to 14 years ago. None of these individuals has suffered immunosuppression that is ob-

viously the result of infection with the attenuated HIV. Seven patients are still alive—all with normal immune function. Four have an undetectable HIV viral load, and three have detectable viral loads—all less than 3000 copies per milliliter. Three patients have died from probably unrelated causes. Two patients died in their 80's, one of disseminated colon cancer and one of cerebrovascular disease, and neither showed signs of immunosuppression resulting from infection with the attenuated HIV, despite their advanced years. The third patient who died had systemic lupus erythematosus and was on immunosuppressive therapy for this when she died of *Pneumocystis carinii* pneumonia—a recognized complication of immunosuppressive therapy.

This experience with a *nef*-deleted HIV in humans is surely more relevant in deciding whether a trial in humans is likely to be safe than consideration of SIV delta *nef* or SIV delta 3 infection in monkeys—a different virus in a different host.

Charles F. Farthing
Chair, Live-Attenuated HIV
Vaccine Subcommittee, IAPAC,
Medical Director, AIDS Healthcare
Foundation, and Department of Medicine,
University of California Medical School,
Los Angeles, CA 90095, USA



PNA DNA	W	M	W	M
	N	N	C	C
Excess PNA -				
197 bp -				


Analysis of W1282X mutation using slab gel format. PCR DNA samples (25 ng) of either wild-type homozygous (N/N) or carrier heterozygous (X/N) were denatured and hybridized with 0.5 pmol of fluorescein labeled wild-type PNA (WT), or mutant PNA (M). Both PNA probes were 15-mers; the PNAs were detected using antiluorescein antibody conjugated to alkaline phosphatase. Perry O'Keefe et al. PNA PreGel Hybridization, an Alternative to Southern Blotting. Proceedings of the National Academy of Sciences, USA. (1996), 93, 14670-14675. Reproduced with permission.

Break the bounds of DNA. Peptide Nucleic Acid (PNA) probes empower your research with superior detection and binding capabilities. Exclusively from PerSeptive Biosystems.

Accelerate discovery with PNA PreGel Hybridization, a swift and precise alternative to Southern Blotting.


Higher affinity. A neutral peptide-like backbone ensures **faster** hybridization. Enhanced **specificity**. PNA probes allow for single base pair discrimination. Remarkable **clarity**. See what you have never seen before.

See PNA. Call PerSeptive Biosystems for a FREE applications overview on PNA probes.



www.pbio.com

US 1.800.899.5858 / Germany +49 6122 9830 0
France +33 134 5230 30 / UK +44 1992 5071 00
Japan +81 3 5570-9050



PerSeptive Biosystems

FAST FORWARD is a trademark of PerSeptive Biosystems, Inc.
©1997 PerSeptive Biosystems, Inc. All rights reserved. Printed in USA.